Alexandria Hammond
Stock Analyst at B of A Securities
(2.79)
# 1,690
Out of 5,154 analysts
15
Total ratings
77.78%
Success rate
14.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $570 → $529 | $432.83 | +22.22% | 3 | Feb 20, 2026 | |
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $230.11 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $115.79 | +16.59% | 2 | Jan 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $759.86 | +51.34% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $27.05 | -7.58% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $52.52 | -23.84% | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $990.33 | +0.98% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $240.40 | -20.97% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $143.93 | -23.57% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $60.29 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $184.87 | - | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Feb 20, 2026
Maintains: Neutral
Price Target: $570 → $529
Current: $432.83
Upside: +22.22%
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $230.11
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $115.79
Upside: +16.59%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $759.86
Upside: +51.34%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $27.05
Upside: -7.58%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $52.52
Upside: -23.84%
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $990.33
Upside: +0.98%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $240.40
Upside: -20.97%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $143.93
Upside: -23.57%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $60.29
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $184.87
Upside: -